Blonanserin
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
- Blonanserin
- Blonanserin: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies
Blonanserin: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies
One-Sentence Summary
Blonanserin is an atypical antipsychotic approved in Japan (marketed as Lonasen®), primarily acting as a D2/D3 and 5-HT2A receptor antagonist for the treatment of schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, with a prediction score of 99.98% — however, there are currently 0 clinical trials and 0 publications supporting this direction. This prediction is classified as a model-only signal and warrants careful scrutiny before any further development.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia (approved in Japan) |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| India Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the India regulatory dataset. Based on pharmacological target data, Blonanserin (CAS 132810-10-7) is a synthetic organic compound that antagonises the D2/D3 dopamine receptors (DRD2, gene ID 1813) and 5-HT2A serotonin receptors (HTR2A, gene ID 3356). This dual receptor blockade profile is the basis for its antipsychotic activity in schizophrenia treatment.
Retinal dystrophy with or without extraocular anomalies is a group of hereditary, progressive photoreceptor and retinal pigment epithelium (RPE) degenerative diseases driven by genetic mutations such as RPGR and RPGRIP1L. While the retina does contain dopaminergic amacrine neurons — which modulate contrast sensitivity and circadian adaptation — their functional role is distinct from the genetic and structural mechanisms underlying inherited retinal dystrophy. Blonanserin’s D2/5-HT2A antagonism has no known pharmacological intersection with photoreceptor structural maintenance or genetic defect repair pathways.
The TxGNN model produces a high numerical score for this pairing, but this is most likely a model false positive. The biological plausibility is very low: the primary pathology in retinal dystrophy is irreversible photoreceptor degeneration driven by structural gene mutations, a disease mechanism that dopamine receptor modulation cannot address. This prediction does not rise above a speculative computational association at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Blonanserin is currently not registered or marketed in India. No product licenses are on file.
Safety Considerations
Drug-Receptor Interactions (Pharmacological Targets): Based on available pharmacology data, Blonanserin acts on the following human receptors:
- 5-HT2A receptor (HTR2A, ENSG00000102468) — antagonism contributes to atypical antipsychotic profile
- D2 receptor (DRD2, ENSG00000149295) — blockade underlies antipsychotic efficacy and extrapyramidal side-effect risk
For full prescribing warnings, contraindications, and drug interaction data, please refer to the Japanese package insert (Lonasen®), as India-specific labelling data is not available.
Conclusion and Next Steps
Decision: Hold
Rationale: There is zero clinical or preclinical evidence supporting Blonanserin’s use in retinal dystrophy. The mechanistic link between D2/5-HT2A receptor antagonism and hereditary photoreceptor degeneration is not established, and the TxGNN high-score prediction is assessed as a likely model false positive for this indication.
To proceed, the following would be needed:
- Mechanistic validation: Identify any credible biological pathway linking D2 or 5-HT2A receptor modulation to photoreceptor/RPE cell survival in retinal dystrophy models
- Preclinical proof-of-concept: In vitro or in vivo studies in retinal dystrophy animal models (e.g., rd1, rd10 mice) before any human study could be considered
- India package insert / safety dossier: Obtain TFDA/CDSCO-equivalent labelling data to complete the safety assessment (Data Gaps DG001 and DG002 must be resolved)
- DrugBank MOA data: Retrieve full mechanism of action profile to enable proper mechanistic relevance scoring
- Regulatory pathway assessment: Confirm whether Blonanserin would require a new drug application in India before any clinical investigation could begin
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.